Back to search

Article

Mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report

2022-09-14

Abstract excerpt

<h4>Background: </h4> Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment. Nevertheless, in localised disease overall 5-year survival rates are below 50% whereas in metastatic spread median progression-free survival rates of 5 months can be expe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b9929c86-88b7-5151-b641-0c1b9cf490aa
DOI
10.21203/rs.3.rs-2057200/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case reportDOI 10.21203/rs.3.rs-2057200/v1
Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targetsSemantic proximity
The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistanceSemantic proximity
Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation.Semantic proximity
Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to ImmunophenotypeSemantic proximity
Chondrosarcoma: biology, genetics, and epigeneticsSemantic proximity
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.Semantic proximity
Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.Semantic proximity
Systemic Therapy for Chondrosarcoma.Semantic proximity
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaSemantic proximity
Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas.Semantic proximity
An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencingSemantic proximity
Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma.Semantic proximity
Select a neighboring publication to make it the new centre.